PROSPECTIVE RANDOMIZED COMPARISON OF INTRAVESICAL WITH PERCUTANEOUS BACILLUS CALMETTE-GUERIN VERSUS INTRAVESICAL BACILLUS CALMETTE-GUERIN IN SUPERFICIAL BLADDER-CANCER

被引：34

作者：

LAMM, DL ^{[1
]}

DEHAVEN, JI ^{[1
]}

SHRIVER, J ^{[1
]}

SAROSDY, MF ^{[1
]}

机构：

[1] UNIV TEXAS,HLTH SCI CTR,DEPT UROL,SAN ANTONIO,TX 78284

来源：

JOURNAL OF UROLOGY | 1991年 / 145卷 / 04期

关键词：

BLADDER NEOPLASMS; CARCINOMA; TRANSITIONAL CELL; BCG VACCINE;

D O I：

10.1016/S0022-5347(17)38439-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Conflicting reports of the necessity for percutaneous bacillus Calmette-Guerin (BCG) administration with intravesical BCG prompted us to evaluate its benefit in a randomized prospective comparison of intravesical versus intravesical with percutaneous BCG therapy. Intravesical Tice BCG was given in a dose of 50 mg. with or without percutaneous BCG weekly for 6 weeks, at 8, 10 and 12 weeks, at 6 months and every 6 months thereafter. Tumor recurrence was documented in 13 of 30 patients (43%) receiving only intravesical BCG and in 15 of 36 patients (42%) receiving intravesical plus percutaneous BCG. The addition of percutaneous BCG to intravesical therapy did not increase treatment efficacy in this study.

引用

页码：738 / 740

页数：3

共 23 条

[1] THE USE OF BACILLUS CALMETTE-GUERIN IN THE THERAPY OF BLADDER-CARCINOMA INSITU [J].